Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-10 10:05 am Sale |
2022-12-31 | 13G | Kura Oncology, Inc. KURA |
James E. Flynn | 2,383,000 3.560% |
-1,130,756 (-32.18%) |
Filing History |
| 2023-02-10 10:03 am Sale |
2022-12-31 | 13G | Inozyme Pharma, Inc. INZY |
James E. Flynn | 0 0.000% |
-2,344,786 (Position Closed) |
Filing History |
| 2023-02-10 10:01 am Unchanged |
2022-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
James E. Flynn | 3,933,137 6.220% |
0 (Unchanged) |
Filing History |
| 2023-02-10 10:00 am Sale |
2022-12-31 | 13G | Aerie Pharmaceuticals, Inc. AERI |
James E. Flynn | 0 0.000% |
-4,695,020 (Position Closed) |
Filing History |
| 2023-02-10 09:58 am Unchanged |
2022-12-31 | 13G | Abeona Therapeutics Inc. ABEO |
James E. Flynn | 1,739,130 5.060% |
0 (Unchanged) |
Filing History |
| 2023-02-10 09:45 am Sale |
2022-12-31 | 13G | IVERIC bio, Inc. ISEE |
James E. Flynn | 3,424,852 2.520% |
-3,176,148 (-48.12%) |
Filing History |
| 2023-02-10 09:44 am Sale |
2022-12-31 | 13G | ImmunoGen, Inc. IMGN |
James E. Flynn | 6,358,314 2.880% |
-8,421,276 (-56.98%) |
Filing History |
| 2023-02-10 09:43 am Unchanged |
2022-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR |
James E. Flynn | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2023-02-10 09:42 am Sale |
2022-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
James E. Flynn | 2,349,228 3.480% |
-3,231,228 (-57.90%) |
Filing History |
| 2023-02-10 09:40 am Sale |
2022-12-31 | 13G | Cogent Biosciences, Inc. COGT |
James E. Flynn | 2,966,345 4.240% |
-2,910,460 (-49.52%) |
Filing History |
| 2023-02-10 09:39 am Sale |
2022-12-31 | 13G | AnaptysBio, Inc. ANAB |
James E. Flynn | 1,161,826 4.090% |
-304,774 (-20.78%) |
Filing History |
| 2023-02-10 09:37 am Sale |
2022-12-31 | 13G | Vigil Neuroscience, Inc. VIGL |
James E. Flynn | 2,052,010 5.770% |
-2,784 (-0.14%) |
Filing History |
| 2023-02-10 09:36 am Sale |
2022-12-31 | 13G | Merus N.V. MRUS |
James E. Flynn | 2,380,438 5.140% |
-141,115 (-5.60%) |
Filing History |
| 2023-02-10 09:34 am Unchanged |
2022-12-31 | 13G | Mirum Pharmaceuticals, Inc. MIRM |
James E. Flynn | 2,032,335 5.510% |
0 (Unchanged) |
Filing History |
| 2023-02-10 09:33 am Purchase |
2022-12-31 | 13G | HilleVax, Inc. HLVX |
James E. Flynn | 2,694,101 8.080% |
76,153 (+2.91%) |
Filing History |
| 2023-02-10 09:32 am Purchase |
2022-12-31 | 13G | Evolus, Inc. EOLS |
James E. Flynn | 3,319,000 5.900% |
288,701 (+9.53%) |
Filing History |
| 2023-02-10 09:30 am Purchase |
2022-12-31 | 13G | Enhabit, Inc. EHAB |
James E. Flynn | 2,996,000 6.040% |
150,000 (+5.27%) |
Filing History |
| 2023-02-10 09:28 am Sale |
2022-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
James E. Flynn | 5,884,448 5.650% |
-176,043 (-2.90%) |
Filing History |
| 2023-02-10 09:27 am Purchase |
2022-12-31 | 13G | Brookdale Senior Living Inc. BKD |
James E. Flynn | 12,679,651 6.790% |
463,090 (+3.79%) |
Filing History |
| 2023-02-01 5:11 pm Purchase |
2023-01-31 | 13G | GeneDx Holdings Corp. WGS |
James E. Flynn | 1,733,094 7.260% |
1,161,928 (+203.43%) |
Filing History |